✦ LIBER ✦

Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance

✍ Scribed by Christiane Pott

Book ID: 117822239
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 573 KB
Volume: 48
Category: Article
ISSN: 1532-8686
DOI: 10.1053/j.seminhematol.2011.05.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Blastoid variant of mantle cell lymphoma

Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease

✍ Christiane Pott; Carsten Schrader; Monika Brüggemann; Matthias Ritgen; Lana Hard 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

Detection and Relevance of Minimal Disea

Detection and Relevance of Minimal Disease in Lymphomas

✍ J.G. Sharp; Wing C. Chan 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 105 KB

Rituximab Induces Effective Clearance of

Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma

✍ Marco Ladetto; Michele Magni; Gloria Pagliano; Federica De Marco; Daniela Drandi 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Minimal residual disease in hematopoieti

Minimal residual disease in hematopoietic malignancy: Technical approaches and clinical significance

✍ Elizabeth Stone; Gregory T. Stelzer 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 982 KB

*701 Detection of Minimal Residual Disea

*701 Detection of Minimal Residual Disease Following Induction Immunochemotherapy Predicts Progression Free Survival in Mantle Cell Lymphoma: Final Results of CALGB 59909

✍ Hongtao Liu; Jeffrey Johnson; Greg Koval; Greg Malnassy; Pamela Ihonor; Dorie Sh 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 143 KB

Minimal residual disease detection in ly

Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms

✍ Simone Ferrero; Daniela Drandi; Barbara Mantoan; Paola Ghione; Paola Omedè; Marc 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

## Abstract Early identification of patients at high risk of relapse is a major goal of current translational research in oncohematology. Minimal residual disease (MRD) detection by polymerase chain reaction‐based methods is currently part of the routine clinical management of patients with acute l